Anti-TNF therapy: Where have we got to in 2005?

Journal of Autoimmunity

Volumn 25, Issue SUPPL., 2005, Pages 26-28

  Feldmann, Marc ^a   Brennan, Fionula M ^a   Foxwell, Brian M J ^a   Taylor, Peter C ^a   Williams, Richard O ^a   Maini, R N ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Anti TNF

Indexed keywords

CERTOLIZUMAB PEGOL; CYCLOPHOSPHAMIDE; ETANERCEPT; HYBRID PROTEIN; I KAPPA B; IMMUNOGLOBULIN F(AB) FRAGMENT; INFLIXIMAB; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6 ANTIBODY; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PHOSPHODIESTERASE IV INHIBITOR; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; STEROID; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANKYLOSING SPONDYLITIS; ARTHRITIS; AUTOIMMUNE DISEASE; CHRONIC INFLAMMATION; CLINICAL TRIAL; CROHN DISEASE; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; HEALTH CARE COST; HOST RESISTANCE; HUMAN; INFECTION; INFECTION RISK; JOINT DEGENERATION; JUVENILE RHEUMATOID ARTHRITIS; LYMPHOMA; NAUSEA AND VOMITING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIATIC ARTHRITIS; REMISSION; REVIEW; RHEUMATOID ARTHRITIS;

ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; CYTOKINES; HUMANS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 28444466261     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2005.09.006     Document Type: Review

References (27)

1. M. Feldmann, F.M. Brennan, and R.N. Maini Role of cytokines in rheumatoid arthritis [Review] [226 refs] Annu Rev Immunol 14 1996 397 440
2. F.M. Brennan, D. Chantry, A. Jackson, R. Maini, and M. Feldmann Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis Lancet 2 1989 244 247
3. C.Q. Chu, M. Field, S. Allard, E. Abney, M. Feldmann, and R.N. Maini Detection of cytokines at the cartilage/pannus junction in patients with rheumatoid arthritis: implications for the role of cytokines in cartilage destruction and repair Br J Rheumatol 31 1992 653 661
4. B.W. Deleuran, C.Q. Chu, M. Field, F.M. Brennan, T. Mitchell, and M. Feldmann Localization of tumor necrosis factor receptors in the synovial tissue and cartilage-pannus junction in patients with rheumatoid arthritis. Implications for local actions of tumor necrosis factor alpha Arthritis Rheum 35 1992 1170 1178
5. R.O. Williams, M. Feldmann, and R.N. Maini Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis Proc Nat Acad Sci U S A 89 1992 9784 9788
6. J. Keffer, L. Probert, H. Cazlaris, S. Georgopoulos, E. Kaslaris, and D. Kioussis Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis EMBO J 10 1991 4025 4031
7. D.W. Hommes, and S.J. van Deventer Targeting tumor necrosis factor-alpha in inflammatory bowel disease: why, how and when? Curr Opin Gastroenterol 19 2003 350 357
8. R.N. Maini, F.C. Breedveld, J.R. Kalden, J.S. Smolen, D. Davis, and J.D. Macfarlane Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis [see comments] Arthritis Rheum 41 1998 1552 1563
9. L. Klareskog, D. van der Heijde, J.P. de Jager, A. Gough, J. Kalden, and M. Malaise Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial Lancet 363 2004 675 681
10. P.E. Lipsky, D.M.F.M. van der Heijde, W. St Clair, D.E. Furst, F. Breedveld, and J. Kalden Infliximab and methotrexate in the treatment of rheumatoid arthritis N Engl J Med 343 2000 1594 1602
11. J. Keane, S.K. Gershon, R.P. Wise, E. Mirabile-Levens, J. Kasznica, and W.D. Schwieterman Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent N Engl J Med 345 2001 1098 1104
12. D.S. Pisetsky, and E.W. St Clair Progress in the treatment of rheumatoid arthritis JAMA 286 2001 2787 2790
13. J. Askling, M. Fored, E. Baecklund, L. Brandt, C. Backlin, and A. Ekbom Hematopoietic malignancies in rheumatoid arthritis. Lymphoma risk and characteristics following TNF-antagonists Ann Rheum Dis 2005
14. M.A. Quinn, P.G. Conaghan, P.J. O'Connor, Z. Karim, A. Greenstein, and A. Brown Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial Arthritis Rheum 52 2005 27 35
15. B. Bresnihan, J.M. Alvaro-Gracia, M. Cobby, M. Doherty, Z. Domljan, and P. Emery Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist [see comments] Arthritis Rheum 41 1998 2196 2204
16. N. Nishimoto, K. Yoshizaki, N. Miyasaka, K. Yamamoto, S. Kawai, and T. Takeuchi Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial Arthritis Rheum 50 2004 1761 1769
17. H. Kazkaz, and D. Isenberg Anti B cell therapy (rituximab) in the treatment of autoimmune diseases Curr Opin Pharmacol 4 2004 398 402
18. B. Beutler, I.W. Milsark, and A.C. Cerami Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin Science 229 1985 869 871
19. C.A. Smith, T. Davis, D. Anderson, L. Solam, M.P. Beckmann, and R. Jerzy A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins Science 248 1990 1019 1023
20. L.W. Moreland, S.W. Baumgartner, M.H. Schiff, E.A. Tindall, R.M. Fleischmann, and A.L. Weaver Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein N Engl J Med 337 1997 141 147
21. J.C. Lee, J.T. Laydon, P.C. McDonnell, T.F. Gallagher, S. Kumar, and D. Green A protein kinase involved in the regulation of inflammatory cytokine biosynthesis Nature 372 1994 739 746
22. S.E. Ross, R.O. Williams, L.J. Mason, C. Mauri, L. Marinova-Mutafchieva, and A.M. Malfait Suppression of TNF-alpha expression, inhibition of Th1 activity, and amelioration of collagen-induced arthritis by rolipram J Immunol 159 1997 6253 6259
23. A.M. Malfait, R. Gallily, P.F. Sumariwalla, A.S. Malik, E. Andreakos, and R. Mechoulam The non-psychoactive cannabis-constitutent cannabidiol is an oral anti-arthritis therapeutic in murine collagen-induced arthritis Proc Nat Acad Sci U S A 97 2000 9561 9566
24. P.F. Sumariwalla, R. Gallily, S. Tchilibon, E. Fride, R. Mechoulam, and M. Feldmann A novel synthetic, non-psychoacive cannabinoid acid (HU-320) with anti-inflammatory properties in murine collagen-induced arthritis Arthritis Rheum 50 2004 985 998
25. N.J. Horwood, T. Mahon, J.P. McDaid, J. Campbell, H. Mano, and F.M. Brennan Bruton's tyrosine kinase is required for lipopolysaccharide-induced tumor necrosis factor alpha production J Exp Med 197 2003 1603 1611
26. M. Feldmann, and R.N. Maini Anti-TNFalpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 19 2001 163 196
27. M. Feldmann, and R.N. Maini TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases Nat Med 9 2003 1245 1250